Background: Rituximab, a key drug used in therapeutic strategies for treatment of CD20+ non-Hodgkin`s lymphoma, can cause drug-induced interstitial lung disease (ILD). Despite recent accumulation of data regarding the clinical features of rituximab-induced ILD, its risk factors have yet to be clarified. Objectives: The purpose of the present study was to investigate the clinical features of and risk factors for rituximab-induced ILD in patients with non-Hodgkin`s lymphoma who undergo treatment with rituximab-containing regimens. Methods: A retrospective study of patients with non-Hodgkin`s lymphoma treated with rituximab was conducted in a tertiary referral center in Korea. We compared various clinical parameters of patients with and without rituximab-induced ILD and determined its risk factors. Results: Of 264 patients with non-Hodgkin`s lymphoma who were treated with rituximab-containing chemotherapy regimens, nine (3.5%) were diagnosed as having rituximab-induced ILD, including clinically suspected cases (n=5). Based on clinical and radiologic findings, the most common pattern was organizing pneumonia (n=7 [78%]). Three patients (33%) for whom treatment failed died from respiratory failure caused by rituximab-induced ILD. Poor ECOG performance status and age were significant risk factor for rituximab-induced ILD (odds ratio [OR] 10.8, 95% confidence interval [CI] 1.6-74.8, p=0.016; and OR 1.1, 95% CI 0.0-1.2, p=0.048, respectively).